Plus Therapeutics, INC Form 4 insider transactions

Kyle Guse, a Director at Plus Therapeutics, Inc., acquired 922 shares of common stock through the vesting of Restricted Stock Units.

Ronald Andrews, a Director at Plus Therapeutics, Inc., reported the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026, as per SEC Form 4 filing.

Plus Therapeutics, Inc. director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026.

Marc Hedrick, CEO of Plus Therapeutics, reports on the vesting of Restricted Stock Units (RSUs) on July 1, 2026, increasing his beneficial ownership of common stock.

An van Es-Johansson, a Director at PLUS THERAPEUTICS, INC., has acquired restricted stock units and stock options.

Richard J. Hawkins, a Director at Plus Therapeutics, Inc., acquired stock options and restricted stock units on May 14, 2026.

Plus Therapeutics, Inc. reports a Form 4 filing detailing the acquisition of stock options and restricted stock units by Director Kyle Guse.

Director Howard Clowes of Plus Therapeutics, Inc. acquired stock options and restricted stock units, indicating continued commitment and potential future equity.

Ronald Asbury, a Director at PLUS THERAPEUTICS, INC., reported transactions involving the acquisition of restricted stock units and stock options.

Andrew Sims, Chief Financial Officer of Plus Therapeutics, Inc., acquired stock options and restricted stock units on May 14, 2026.

Marc Hedrick, CEO of Plus Therapeutics, reported transactions involving restricted stock units and stock options on May 14, 2026.

Chief Development Officer Eric Joseph Daniels received a grant of 20,000 restricted stock units and 20,000 stock options.

PLUS THERAPEUTICS, INC. Chief Financial Officer, Andrew Sims, reported the vesting of 67,452 Restricted Stock Units into common stock.

PLUS THERAPEUTICS CEO Marc H. Hedrick reported future vesting of Restricted Stock Units, impacting his beneficial ownership of common stock.

Plus Therapeutics CFO Andrew Sims reported the acquisition of 349,542 Restricted Stock Units and 349,541 stock options, increasing his beneficial ownership.

PLUS THERAPEUTICS, INC. CEO Marc H. Hedrick received 2,419,582 Restricted Stock Units and 2,419,582 stock options, aligning executive incentives with long-term company performance.

PLUS THERAPEUTICS CEO Marc H. Hedrick reported the vesting of 159,681 Restricted Stock Units into common stock, increasing his direct beneficial ownership.

PLUS THERAPEUTICS CFO Andrew Sims acquired 38,323 shares of common stock through the vesting of Restricted Stock Units on January 1, 2026.

PLUS THERAPEUTICS CFO Andrew Sims acquired 20,000 shares of common stock at an average price of $0.51.

PLUS THERAPEUTICS CFO Andrew Sims filed an amended Form 4 to correct the vesting schedule for 459,878 Restricted Stock Units.

PLUS THERAPEUTICS CEO Marc H. Hedrick reported the vesting of 159,681 Restricted Stock Units, converting them into common stock.

PLUS THERAPEUTICS, INC. CEO Marc H. Hedrick filed an amended Form 4 to correct the vesting schedule for his Restricted Stock Units.

PLUS THERAPEUTICS CFO Andrew Sims reported the vesting of 38,323 Restricted Stock Units, increasing his direct beneficial ownership of common stock.

PLUS THERAPEUTICS Director Robert P. Lenk acquired 110,000 shares of common stock at $0.4889 per share in a pre-planned transaction.

PLUS THERAPEUTICS Director Kyle Guse was granted 337,794 stock options with an exercise price of $0.5744.

PLUS THERAPEUTICS, INC. CEO Marc H. Hedrick was granted future stock options and restricted stock units totaling over 7.6 million shares, vesting over three to four years.

PLUS Therapeutics Director Richard J Hawkins was granted 397,794 stock options with an exercise price of $0.5744, vesting over 12 months.

PLUS THERAPEUTICS, INC. Director Howard Clowes was granted 297,794 stock options with an exercise price of $0.5744 per share.

PLUS THERAPEUTICS, INC. Director Robert P. Lenk was granted 297,794 stock options with an exercise price of $0.5744, vesting over 12 months.

PLUS Therapeutics' Chief Financial Officer, Andrew Sims, was granted stock options and restricted stock units.